Pharmaceuticals, Biotechnology and Life Sciences
Cooley lawyers working in the technology and life sciences industries have been advising some of the world’s most innovative companies as they seek to deliver products and services to battle myriad aspects of the COVID-19 pandemic.
GSK expects gross proceeds from the divestment to be £3.4 billion and net proceeds from the divestment to be £2.9 billion.
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19, in which GSK will make an equity investment in Vir of $250 million, to gain access to Vir’s technology.
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD) Zejula is…
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, this week said that the European Commission has granted Marketing Authorisation for HIV-1 infection treatment, Dovato.
Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront
DUBLIN–(BUSINESS WIRE)–The “Global Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
GSK and Kyowa Hakko Kirin will together commercialize in Japan the treatment of chronic kidney disease related anaemina, which GKS…